The share price of S&P/ASX 300 Index (ASX: XKO) stock Mayne Pharma Group Ltd (ASX: MYX) has soared since the company dropped its half-year earnings on Tuesday morning.
Right now, the pharmaceutical manufacturerâs stock is trading at $4 â 27% higher than it was before it broke a trading halt with news of its results, a divestment, and its capital return.
Letâs take a closer look at whatâs been going right for the ASX 300 share this week.
ASX 300 share Mayne Pharma rockets 27% in 2 sessions
Here are the key takeaways from Mayne Pharmaâs first-half earnings:
- $101.2 million of revenue excluding discontinued segments â a 33% drop on that of the prior comparable period (pcp)
- Earnings before interest, tax, depreciation, and amortisation (EBITDA) came to a $99.2 million loss
- $129.2 million net loss after tax â down from a $66.3 million loss in the pcp
- Basic earnings per share (EPS) came in at 17.6 cents
- No dividend declared
The companyâs earnings were dinted by lower revenues, driven by higher inventory levels, discontinued products, and foreign exchange losses.
The companyâs branded products division saw revenue more than triple to $13.4 million last half amid strong growth in NEXSTELIS sales. Its portfolio products division saw revenue fall 49% to $60.1 million. Finally, its international segmentâs revenue was flat at $27.6 million.
What else did the company announce this week?
The Mayne Pharma share price was put into a trading halt on Monday morning, returning to trade on Tuesday, as the ASX 300 company prepared to release news of a material divestment and its capital management.
Later that day, it announced the sale of its US retail generics portfolio business for up to US$90 million cash and up to US$15 million of contingent milestone payments.
The move supports the companyâs aim to transform into a speciality pharmaceutical company with leading positions in womenâs health and dermatology.
It also announced the cancellation of its $113 million capital return on Tuesday. It said the return was no longer in the companyâs best interests.
What did management say?
Mayne Pharma CEO Shawn Patrick OâBrien commented on the news seemingly driving the ASX 300 share sky-high in recent sessions, saying:
We have taken decisive action this half to address the issues that have created the disappointing results in both our PPD and International businesses.
We are creating a leaner company with strong commercial and sales execution capabilities and [with the sale of the US retail generics business] we move a step closer to achieving our goal of generating operating cash and returning the business to profitability.
The board is supportive of our strategy and ambition, and the cancellation of the capital return is a prudent step to retain balance sheet flexibility whilst we drive improved operating performance, and the board considers the appropriate capital structure to support profitable growth and a restoration of shareholder value.
Whatâs next?
The company heralded an encouraging start to the second half. It flagged improvement in its dermatology segment and positive impacts from the scaling up of its US womenâs health business.
The latter is on track to exit financial year 2023 with a positive run rate contribution. Meanwhile, the newly acquired TherapeuticsMD portfolio is expected to deliver positive earnings in the second half.
At the same time, launches of various products are expected to drive growth across the company.
Maybe Pharma share price underperforms the ASX 300
Despite this weekâs surge, the Mayne Pharma share price is still in the longer-term red.
It has fallen 5% so far this year and 13% over the last 12 months.
For comparison, the ASX 300 has gained 4% year to date and 2% over the last 12 months.
The post Guess which ASX 300 share has rocketed 27% in 2 days since reporting appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mayne Pharma Group Limited right now?
Before you consider Mayne Pharma Group Limited, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mayne Pharma Group Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/uzAU0KN
Stock Pick 